Alfredo Addeo MD

@GlopesMd New SOC in this setting, despite the small study size. Best data around . Wondering if we will see at some point some chemo -OSI data here

Significant #ASCO26 update (Abstract 8501, CHRYSALIS-2): 1L amivantamab + lazertinib in atypical EGFR+ NSCLC delivers median OS of 41 months — nearly double afatinib's ~19.4 mo in this hard-to-treat subgroup. 46% alive at 4 yrs, 20% still on 1L therapy. Atypical EGFR finally catching up. #LCSM @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti meetings.asco.org/meetings/2026-…

🚨🔥@OncoAlert HOT OFF THE PRESS. @ASCO Annual Meeting #ASCO26 #Abstracts JUST #RELEASED. Looking forward & ready for: ⭐️GREAT ✅#Science ✅#Research ✅#Education ✅Practice Changing #Studies 🙏It’s an #EraOfHope for #Patients with #Cancer. 👇🏼 bit.ly/3PAl4Qo

🚨 Save the Date! How will the therapy landscape of lung cancer shift by end of 2026? Whether onsite in Lausanne or live online, learn more at the ILCS hosted by @peters_solange & @Alfdoc2 alongside a global faculty. ・Friday, Nov 13th, 2026 ・Lausanne, Switzerland & Live Online

Our new article is out in EJC with Sahar van Waalwijk and David Thomas! Reimbursement decisions may be less strongly backed by clinical evidence and more driven by the unmet needs, e.g. reimbursement in childhood cancers where the data are only available for adults. However, this is unprecedented in any public healthcare:  In Australia, the PBAC is reimbursing ipilimumab plus nivolumab for tumour‑agnostic use, even though the DART trial showed an overall response rate of only 12%, with significant toxicities. Read why we believe such a reimbursement decision is unwarranted, and what alternatives we propose. theoncologyshot.com/p/world-first-…

How will the therapeutic landscape of thoracic oncology shift by the end of 2026? Join our chairs @peters_solange & @Alfdoc2 for the International Lung Cancer Summit 2026. Whether onsite in Lausanne or live online, we’ll synthesize a year of clinical breakthroughs to define the next standards in care. 🗓️ Friday, Nov 13th, 2026 📍 Lausanne, Switzerland & Live Online 🚀 Registration opens 1st June Save the date and mark your calendars! ⬇️ #ILCS" target="_blank" rel="nofollow noopener">lungsummit.org/#ILCS

How are experts approaching resectable #EGFR -mutant #NSCLC in clinical practice? 🇮🇹 In this Italian-language episode of #LungCancerConsidered, @Alfdoc2 joins @AndrearicFili and @PiergiorgioSolli for a Virtual Tumor Board discussion on treatment planning and multidisciplinary care. 🎧 bit.ly/4dv1KgB #LungCancer

@NReguart @charocampelo @EnriquetaFelip @peters_solange Great trio. I will dial in

Together with @EnriquetaFelip we are delighted to host this year’s Meet the Professor in Thoracic Tumors with Dr. Solange Peters @peters_solange: insight and inspiration at its best. Save the date!

Great exchange of ideas at #ESMOInFocus Lung Cancer Romania 🇷🇴.Honored to participate in this excellent meeting focused on the evolving landscape of thoracic oncology.Pleased to share the stage with outstanding colleagues @gbanna74 @MARIANOPROVENCI #ESMOInFocus

May is Thymic Malignancy Awareness Month! Join us for a FREE webinar series covering the latest in thymic epithelial tumors. Register: itmig.org/tmam/ 📋 May 20 — Clinical Guidelines Updates 🏥 May 20 — Multidisciplinary Care: Surgery to QoL 🧬 May 22 — Clinical Trials & Emerging Therapies 🔬 May 28 — Challenges in Thymic Tumor Pathology 🌍 Jun 9 — Treatment Access Worldwide @Itmig_society

@Papa_Heme Don’t be , I have never been. A suggestion to the younger me “ speak always your mind, try to be constructive, do not oversimplify situations that you do not know or understand completely “.

Academic oncology has gotten bad. Many are scared to share their true opinions on matters as leaders in the field will black ball them. True innovation thrives on diversity in view points.

@CentralParkWMD @oncodaily @OncoDailyGI @OncBrothers @brunolarvol @MSK_DeptOfMed @MSKCancerCenter @lustgartenfdn @NatureMedicine @CD_AACR @CpcrMsk @GiOncNow *my not may ..concern …

@CentralParkWMD @oncodaily @OncoDailyGI @OncBrothers @brunolarvol @MSK_DeptOfMed @MSKCancerCenter @lustgartenfdn @NatureMedicine @CD_AACR @CpcrMsk @GiOncNow I have huge respect for you, the team and I am incredibly grateful to patients for helping us to raise the bar. The data are indeed encouraging indeed. May main concern is how to handle tox, skin tox. Any tips? I don’t think this is the typical skin tox we are used to see

1/n Daraxonrasib (RMC-6236), the first-in-human oral 💊RAS(ON) multi-selective tri-complex inhibitor, in previously treated RAS-mutated pancreatic cancer phase I/II study is now published in the New England Journal of Medicine @NEJM A novel💡 way to shut down ⚔️RAS, one of the most important oncogenic drivers in cancer that had long been considered “undruggable.” 🔗nejm.org/doi/full/10.10… Shout out to Brian Wolpin, @CentralParkWMD @GarridoLagunaMD @AlexSpiraMDPhD @salmanpunekar @MeredithPelster @bherzbergmd Nilo Azad Aparna Hegde @DavidHongMD and the whole team who dedicated to this study. @EileenMOReilly #HBP #HumansBeyondPatients

@NarjustFlorezMD @NEJM @DanaFarber Congrats

Grateful to take on a new role as Associate Editor of New England Journal Medicine Clinician. Advancing how we communicate science is key to delivering better, more informed care for our patients. @NEJM @DanaFarber clinician.nejm.org/editors/AU3755

@TracyBethHoeg @Timothee_MD Definitely brilliant, smart and hilarious.Totally bummed he had left FDA I admire the courage to stand his ground. In society where being a yes-men is convenient I can only have respect and admiration for someone like him who chooses to follow and defend his principles

Thursday was Vinay's last official day at the FDA I'm very grateful I had another chance to work w him over the last year He is brilliant, hilarious, creative & did transformational work at the FDA Thanks to him for his service I look forward to following his future work ☀️

Delighted to partner with @wearemedsir & @cancertrials_ie for 🇮🇪’s first ‘IIT Think Tank’ to develop investigator-led clinical trials Join us in @RCSI_Irl today for a dynamic discussion - new trial concepts, keynote by @FordePatrick, & more! @CancerCentreIre @AngelaClaytonL1

@Guidolino8 Partita bruttissima… ho visto quasi tutte le partite del Napoli quest anno e veramente non ricordo un calcio così noioso, lento, macchinoso come questo. Una schifezza

Il Napoli ferma il Como e avvicina la Champions League, adesso mancano 3 punti per la Coppa delle grandi orecchie. Il Napoli ha chiuso in crescendo, ma il Como avrebbe meritato il successo. In ogni modo un punto a Como va bene. Nelle ultime 3 gare bisogna cercare di vincerle tutte per arrivare secondi. MVP Milinkovic Savic

Starting now our post-graduate session on oesophago-gastric cancers at HUG. Proud to see our trainees leading the presentations and delivering such high-quality discussions. Learning and teaching remain at the heart of becoming an excellent physician @hug_ge

Mutations in the tyrosine kinase domain of EGFR represent one of the most common druggable alterations in #NSCLC. This recent review provides a comprehensive clinical overview of the management of patients with EGFR-mutant NSCLC. acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert @Alfdoc2

What are plenary sessions for ASCO 2026 ? Titles are just out Watch out 🙂👇 @ASCO #asco2026 @Alfdoc2 @APassaroMD @dr_yakupergun @OncBrothers @OncoAlert @MedwatchKate @FordePatrick @DrJNaidoo @MyriamChalabi @DrChoueiri